Cannabidivarin (CBDV) is a non-psychoactive cannabinoid found in Cannabis. It is a homolog of cannabidiol (CBD), with the side-chain shortened by two. Cannabidivarin, also known as cannabidivarol or CBDV, is a non-psychoactive cannabinoid found within [DB]. It is one of over cannabinoids. Cannabidivarin, also known as cannabidivarol or CBDV, is a non-psychoactive cannabinoid found within Medical Cannabis. It is one of over.
or Cannabidivarin CBDV
Wittig derivatization of sesquiterpenoid polygodial leads to cytostatic agents with activity against drug resistant cancer cells and capable of pyrrolylation of primary amines. Citation Statistics Citations 0 10 20 30 '14 '15 '16 '17 '18 ' Semantic Scholar estimates that this publication has citations based on the available data. See our FAQ for additional information. References Publications referenced by this paper.
Showing of 46 references. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures Nicholas A. Jones , Sarah E. Cannabidivarin is anticonvulsant in mouse and rat. Hill , Marion S. Caterina , John T Cunningham. Learn more about optional signed reviews and how to write a better rebuttal letter. The major problem with this paper is the lack of any insight on the molecular mechanism underlying the effect of CBVD.
This evidence could be of master importance to dissect the effect of the drug from that of decreased seizures activity in epilepsy. The Authors draw a conclusion based on changes in mRNA expression that could be misleading for the scientific community.
The Authors should try to address the molecular mechanism with few experiments and provide an hypothesis for the effect of CBVD at molecular level. After modifications and explanations added after the first submission, still the principal research question is not answered. Specifically all the results presented by the authors can likely be a consequence of reduced seizures and not an effect mediated by CBDV. The finding, still seems not appropriate and misunderstaning on the role of cannabinoid system in epilepsy can originate.
The paper still do not represent an advancement in understanding the role of cannabinoid system in epilepsy. Lack of novelty and lack of clarification of the role of CBVD in epilepsy are the major problems of this paper. Still all the results presented by the authors can be addressed to a decreased seizures activity, thus the possible effect of CBVD is not clarified.
The paper mainly describes an association between seizure and gene expression changes. Majority of data was already reported. The study would benefit from investigations on protective role of CBVD on seizures.
Figure 1 legend has spaces between first letter and rest of word for 'm edian' l atency' and 'v ehicle'. Figure 1 legend for A and B is very terse. It might be better to indicate 'plot showing latency to seizure' or similar.
Units in Figure 1 A and B are not indicated on the axes e. Units of Figures 1 and 2 axis labels differ in capitalisation Seizure Severity and Seizure severity. The experimental design and statistics were of high standard.
Was a two-tailed test strictly necessary given that expected a priori assumption would be for a unidirectional change towards lower severity and longer latency? In the first part of the introduction authors first described how agonists of CB1R are anticonvulsant and antiepileptiform drugs. Authors should better explain these differences otherwise readers can be confused about the activity of cannabinoids on seizures and epilepsy. The description of the seizures severity in methods section should be better explained and not only referenced.
Experiments are not well conducted for the purpose of the paper. Authors wanted to clarify the molecular mechanism involved in CBDV-mediated seizure suppression. With the experiments performed in this paper they only show that seizures induce an upregulation of several genes already know , and that suppressing seiures with CBVD can partially reduce the seizures-induced upregulation.
There is not molecular mechanism about the effect of CBVD.
Military Funds Research of Cannabis-based Autism Treatment for Kids
Introduction To Phytocannabinoids And Cannabidivarin (CBDV). For too long has humankind been exposed to the cannabis plant without the. Autism Spectrum Disorder, Drug: Cannabidivarin (CBDV) Drug: Matched Weight-based dosing of 10 mg/kg/day of CBDV for 12 weeks. Cannabidivarin (CBDV) is a non-psychoactive cannabinoid that will not cause the euphoric feeling of being “high.” It is found more prevalently in indica strains, .